Optimal Hormone Levels for Transgender Women on HRT
For transgender women on gender-affirming hormone therapy, target testosterone levels below 50 ng/dL (the female range) and estradiol levels in the adult female physiologic range, though recent evidence challenges the traditional 100-200 pg/mL guideline as lacking robust support for optimal feminization. 1
Testosterone Targets
The primary goal is testosterone suppression to <50 ng/dL, which represents the cisgender female range 1. This target is consistently achievable:
- Most patients reach this goal within 2 months on appropriate estradiol dosing 2
- Injectable estradiol monotherapy achieves testosterone suppression in 82.6% of patients without requiring additional antiandrogens 3
- The addition of spironolactone does not provide additional testosterone suppression benefit 3
Estradiol Targets: The Evidence Gap
The widely cited 100-200 pg/mL range lacks evidence-based support. A 2025 systematic review found no studies demonstrating this range provides optimal feminizing outcomes or reduces adverse events 4. The guidelines recommend "adult levels of estradiol" to produce feminine physical attributes 1, but specific numeric targets remain poorly validated.
Practical Estradiol Dosing Considerations
Recent research reveals current dosing recommendations often lead to supratherapeutic levels:
- Injectable estradiol: Start at ≤5 mg weekly (not the guideline's 2-10 mg), as higher doses produce supraphysiologic levels 5
- Average effective dose: 3.7-4 mg weekly achieves mean estradiol of 232-248 pg/mL with excellent testosterone suppression 6, 3
- Transdermal estradiol: 1-2 patches of 0.1 mg/24 hours suppress testosterone more rapidly than sublingual routes 2
Route-Specific Differences
Transdermal administration offers advantages over sublingual:
- More rapid testosterone suppression
- Lower estrone levels (avoiding excessive estrone-to-estradiol ratios)
- Continuous rather than pulsed exposure appears more effective 2
- No benefit to twice-daily versus once-daily sublingual dosing 2
Monitoring Strategy
Check hormone levels at 3-6 month intervals initially 7, then adjust based on:
- Testosterone suppression (primary endpoint: <50 ng/dL)
- Clinical feminization (breast development, body composition changes, reduced facial/body hair)
- Estradiol levels (avoid supraphysiologic levels that increase VTE risk without additional benefit)
- Timing of blood draw: For injectable estradiol, fewer days since injection correlates with lower testosterone 3
Critical Safety Considerations
Avoid excessive estradiol dosing due to:
- Increased venous thromboembolism risk (3-fold increase in cardiovascular death) 1
- No evidence that levels >200 pg/mL improve feminization 4
- Ethinyl estradiol carries higher VTE risk than bioidentical estradiol 1
Progestins are not recommended by the Endocrine Society due to breast cancer, thromboembolism, and stroke risks in postmenopausal women, with no proven benefit for breast development in transgender women 1. One retrospective study found patients discontinued progesterone due to lack of measurable effects or poor mood 1.
Antiandrogen Use
Spironolactone may be unnecessary with adequate estradiol dosing:
- No additional testosterone suppression when combined with injectable estradiol 3
- May result in lower estradiol levels (285 vs 427 pg/mL for monotherapy) 6
- Consider estradiol monotherapy first, particularly with injectable or transdermal routes
Quality of Life Outcomes
Gender-affirming hormone therapy demonstrates strong evidence for improving quality of life and relieving psychological distress from gender dysphoria 8. Physical changes include: